Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 33Carcinoma, Hepatocellular 27Neoplasms 19Colorectal Neoplasms 18Carcinoma, Non-Small-Cell Lung 16Stomach Neoplasms 15Leukemia, Myeloid, Acute 15Prostatic Neoplasms 12Lung Neoplasms 12Colonic Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Rectal Neoplasms 10Neoplasm Metastasis 8Leukemia 8Pancreatic Neoplasms 7NSCLC 6Multiple Myeloma 6Liver Neoplasms 6Esophageal Neoplasms 6Glioblastoma 5Small Cell Lung Carcinoma 4Recurrence 4Polycystic Ovary Syndrome 4Nasopharyngeal Carcinoma 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Head and Neck Neoplasms 4Gestational Trophoblastic Disease 4Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4

Interventions

pembrolizumab 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × Nonsquamous Non-small Cell Lung Cancer × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡